DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.
DURECt 公司（納斯達克：DRRX）是一家處於後期階段的生物製藥公司，正在開創表觀遺傳療法的開發，以改變嚴重和危及生命的疾病，如急性器官損傷的治療。今天宣佈將其 ALZEt 系列滲透泵出售給 Lafayette Instrument Co.（LIC），該公司是 Branfod Castle Partners II, L.P. 的投資組合公司，專注於北美的股權投資。
) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation () is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer.">
) 是一家處於後期階段的生物製藥公司，正在開創針對失調的 DNA 甲基化的表觀遺傳療法，以改變嚴重和危及生命的疾病的治療，包括急性器官損傷和癌症。" alt="DURECt 公司（）是一家處於後期階段的生物製藥公司，正在開創針對失調的 DNA 甲基化的表觀遺傳療法，以改變嚴重和危及生命的疾病的治療，包括急性器官損傷和癌症。"
Under the terms of the agreement, LIC paid DURECT $17.5 million in exchange for certain assets and liabilities associated with the ALZET product line. Simultaneous with this transaction, DURECT has paid off all remaining obligations under the term loan agreement with Oxford Finance LLC.
根據協議條款，LIC 向 DURECt 支付了1750萬美國美元，以換取與 ALZEt 產品線相關的某些資產和負債。與此交易同時進行，DURECt 已經償還了與 Oxford Finance LLC 簽訂的定期貸款協議下所有剩餘的義務。
譯文內容由第三人軟體翻譯。